Alice Melão,  —

Ovid Therapeutics has initiated the Phase 2 ROCKET clinical trial to assess the safety, tolerability, and efficacy of OV101 (gaboxadol) as a treatment for adolescents and young adults with fragile X syndrome. The study is expected to enroll about 30 male patients with clinically diagnosed fragile X syndrome, between…

Babies with fragile X syndrome have less-developed brain white matter compared to those without the syndrome, according to researchers.  Their study, “Development of White Matter Circuitry in Infants With Fragile X Syndrome,” was published in JAMA Psychiatry. Fragile X syndrome is caused by mutations in the FMR1…

Mice that lack the gene responsible for fragile X syndrome have similar changes in brain activity in the auditory cortex as those reported in humans. The study with that finding, “Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome,” was published in the journal of Neurobiology…

Patients with fragile X syndrome have faster protein synthesis and increased protein levels than healthy people, according to a recent study. These findings suggest that protein synthesis alterations could be an important biomarker of the disease and play an important role in its development. The study, “Protein…

GW Pharmaceuticals is going to increase its focus on the development of its investigational, cannabinoid-based therapy GWP42006 to treat autism spectrum disorders (ASD), including Fragile X, the company announced. According to a press release, the company’s decision is based on recent results of a clinical trial in…

Interventions focused on improving mindfulness and acceptance may promote the health and well-being of mothers who have children with fragile X syndrome (FXS), as well as having important health implications for all individuals with an FMR1 premutation, a study finds. The study, “Mindfulness and Acceptance…